Mirum Pharmaceuticals (NasdaqGM:MIRM) reported positive primary endpoint results from its Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV). The trial showed robust antiviral ...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an ...
Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) ...
- AZURE-1 and AZURE-4 to form the basis of Mirum’s U.S. BLA Submission Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase ...
Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results